Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Ribavirin Stories

2012-04-18 22:21:49

BARCELONA, Spain, April 19, 2012 /PRNewswire/ -- Further data shows PegIFN-lambda's comparable efficacy but better safety profile than PegIFN-alpha New data presented at the International Liver Congress(TM) 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials[1],[2],[3],[4],[5],[6] confirm that combinations of antivirals offer the hope of...

2012-04-18 22:21:37

BARCELONA, Spain and RIDGEFIELD, Conn., April 19, 2012 /PRNewswire/ -- New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.( )This descriptive sub-analysis from SOUND-C2, a Phase 2b study evaluating interferon-free...

2012-04-18 22:21:33

BARCELONA, Spain and RIDGEFIELD, Conn., April 19, 2012 /PRNewswire/ -- New data from a pre-specified interim analysis of the Phase 2b SOUND-C2 study show that 68 percent of genotype-1 (GT1) hepatitis C virus (HCV) patients achieved sustained viral response 12 weeks after the end of treatment (SVR12) with Boehringer Ingelheim's investigational direct-acting antiviral compounds - the protease inhibitor BI 201335 and polymerase inhibitor BI 207127 - plus ribavirin (RBV), without interferon....

2012-04-18 22:21:25

ABBOTT PARK, Ill., and WATERTOWN, Mass., April 19, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced data from "Co-Pilot," an interferon-free, Phase 2 study of Abbott's direct-acting antiviral medicines for the treatment of hepatitis C (HCV) that found that more than 90 percent of patients new to HCV treatment achieved sustained viral response through 12 weeks (SVR12). Results were released today at a press conference at the International Liver Congress 2012 (ILC...

2012-04-18 06:27:44

BARCELONA, Spain, April 18, 2012 /PRNewswire/ -- - Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The data shows that similar...

2012-04-04 06:27:17

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress(TM) 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral...

2012-04-04 06:26:54

BEERSE, Belgium, April 4, 2012 /PRNewswire/ -- Not Intended for US Journalists - Analysis to be presented at European Association for the Study of the Liver (EASL) 2012 shows clinical and cost-effectiveness regardless of IL28B subtype - Janssen Pharmaceutica NV (Janssen) will present a cost-effectiveness analysis for INCIVO(telaprevir) at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The analysis...

2012-04-04 06:26:49

ABBOTT PARK Ill., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress(TM) 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Abstracts for the meeting were published online today. In the study known as "Co-Pilot," different doses of ABT-450/r, plus...

2012-03-13 02:30:00

HUDDINGE, Sweden, March 13, 2012 /PRNewswire/ -- - Study in previous non-responder Hepatitis C genotype-1 infected patients - Study in Hepatitis C genotype-4 infected patients MedivirAB (OMX: MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced...

2012-02-22 06:13:34

(Ivanhoe Newswire) — Nearly four million people in the United States are infected with genotype-1 hepatitis C – a virus that attacks the liver, causing swelling, scarring, cancers and the need for transplants. And unlike hepatitis B, there is no vaccine for hepatitis C, until now. Up until last summer, treating people with hepatitis C was a gamble, with many side effects, including anemia, vomiting, hair loss and depression. "These treatments are very uncomfortable and long...


Latest Ribavirin Reference Libraries

0_b3d737125981cbedce0bb0c8511e6b65
2011-02-17 15:14:03

Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...

More Articles (1 articles) »